Study confirms benefits of transcatheter aortic valve replacement over 3 years

A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery. Results of the PARTNER Cohort B trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

TAVR is the recommended treatment for patients with who are not suitable candidates for surgery. Outcomes beyond two years in such patients have not yet been extensively studied.

Inoperable patients with severe symptomatic aortic stenosis (AS) were randomly assigned to transfemoral TAVR or to standard therapy (which often included balloon aortic valvuloplasty) in the PARTNER trial. Data on three-year outcomes were analyzed according to intention to treat (ITT).

A total of 358 patients underwent randomization at 21 centers. The Kaplan Meier estimated rates of death at three years were 54.1 percent in the TAVR group and 80.9 percent in the standard-therapy group (P<0.0001); corresponding rates of cardiac death were 41.4 percent and 74.5 percent (P<0.0001). The survival advantage associated with TAVR that was initially observed at one year persisted during the subsequent years.

"After three years of follow-up, the benefits of TAVR were sustained as measured by all cause mortality, , repeat hospitalization, and functional status," said one of the investigators, E. Murat Tuzcu, MD. Dr. Tuzcu is Professor of Medicine and Vice-Chairman of the Department of Cardiology in the Sydell and Arnold Heart & Vascular Institute at the Cleveland Clinic.

"Three-year data continue to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates," said Dr. Tuzcu.

The results of PARTNER Cohort B Three Year will be presented on Wednesday October 24 at 12:17 PM EST in the Main Arena (Hall D) of the Miami Beach Convention Center.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Use of drug-eluting stents may cut in-hospital mortality

3 hours ago

(HealthDay)—Use of drug-eluting stents (DES) rather than bare-metal stents (BMS) for percutaneous coronary intervention (PCI) is associated with lower rates of in-hospital mortality, according to research ...

Gel implant might help fight heart failure

3 hours ago

(HealthDay)—Injecting beads of gel into the wall of a still-beating heart has the potential to improve the health of patients with severe heart failure, according to a new study.

Obesity fuels silent heart damage

5 hours ago

Using an ultrasensitive blood test to detect the presence of a protein that heralds heart muscle injury, researchers from Johns Hopkins and elsewhere have found that obese people without overt heart disease ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.